LDL-C–Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes-Reference-Cited by-同舟云学术

LDL-C–Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes

Published:2024-01-30 Issue:5 Volume:149 Page:363-366
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Santos Raul D.¹²^ORCID,Cuchel Marina³^ORCID

Affiliation:

1. Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Brazil (R.D.S.).

2. Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil (R.D.S.).

3. Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia (M.C.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference15 articles.

1. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

2. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study

3. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

4. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial

5. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving Concepts of the SCORE System: Subtracting Cholesterol from Risk Estimation: A Way for a Healthy Longevity?;Life;2024-05-24